Zavegepant hydrochlorideProduct ingredient for Zavegepant

Name
Zavegepant hydrochloride
Drug Entry
Zavegepant

Zavegepant (BHV-3500) is a calcitonin gene-related peptide (CGRP) receptor antagonist.5 CGRP is released from sensory nerves and acts as a strong vasodilator, and thanks to these properties, it is involved in pain pathways. CGRP receptors are expressed in the central and peripheral nervous system; however, CGRP does not cross the blood-brain barrier, suggesting that it acts on peripheral nerves. In migraine, CGRP innervates pain-producing meningeal blood vessels and is released by trigeminal nerve stimulation. Since they inhibit these mechanisms and desensitize neuronal circuits, the use of CGRP receptor antagonists is beneficial in the treatment of migraine.2

Small molecule CGRP antagonists are also known as "gepants", and this category includes other drugs such as rimegepant and ubrogepant. Zavegepant is a third-generation CGRP receptor antagonist that is small in size and highly soluble. Due to its pharmacological properties, it can be administered intranasally.1,2 In March 2023, the FDA approved the use of zavegepant nasal spray for the acute treatment of migraine with or without aura in adults.5,6 A clinical trial (NCT04804033) is currently investigating the efficacy and safety of oral zavegepant in migraine prevention, and another one (NCT04987944) is evaluating the safety and efficacy of oral zavegepant (150 mg bid) in subjects with mild allergic asthma.3

Accession Number
DBSALT003479
Structure
Synonyms
4-(1,2-DIHYDRO-2-OXO-3-QUINOLINYL)-N-((1R)-1-((7-METHYL-1H-INDAZOL-5-YL)METHYL)-2-(4-(1-METHYL-4-PIPERIDINYL)-1-PIPERAZINYL)-2-OXOETHYL)-1-PIPERIDINECARBOXAMIDE HYDROCHLORIDE / BHV-3500 HYDROCHLORIDE
External IDs
BMS-742413-03
UNII
000QCM6HAL
CAS Number
1414976-20-7
Weight
Average: 675.28
Monoisotopic: 674.3459651
Chemical Formula
C36H47ClN8O3
InChI Key
VQDUWCSSPSOSNA-RYWNGCACSA-N
InChI
InChI=1S/C36H46N8O3.ClH/c1-24-19-25(20-28-23-37-40-33(24)28)21-32(35(46)43-17-15-42(16-18-43)29-9-11-41(2)12-10-29)39-36(47)44-13-7-26(8-14-44)30-22-27-5-3-4-6-31(27)38-34(30)45;/h3-6,19-20,22-23,26,29,32H,7-18,21H2,1-2H3,(H,37,40)(H,38,45)(H,39,47);1H/t32-;/m1./s1
IUPAC Name
N-[(2R)-3-(7-methyl-1H-indazol-5-yl)-1-[4-(1-methylpiperidin-4-yl)piperazin-1-yl]-1-oxopropan-2-yl]-4-(2-oxo-1,2-dihydroquinolin-3-yl)piperidine-1-carboxamide hydrochloride
SMILES
Cl.CN1CCC(CC1)N1CCN(CC1)C(=O)[C@@H](CC1=CC2=C(NN=C2)C(C)=C1)NC(=O)N1CCC(CC1)C1=CC2=C(NC1=O)C=CC=C2
ChemSpider
81367517
ChEMBL
CHEMBL4650220
Wikipedia
Zavegepant
Predicted Properties
PropertyValueSource
logP2.14Chemaxon
pKa (Strongest Acidic)11.33Chemaxon
pKa (Strongest Basic)8.79Chemaxon
Physiological Charge1Chemaxon
Hydrogen Acceptor Count6Chemaxon
Hydrogen Donor Count3Chemaxon
Polar Surface Area116.91 Å2Chemaxon
Rotatable Bond Count6Chemaxon
Refractivity186.53 m3·mol-1Chemaxon
Polarizability71.37 Å3Chemaxon
Number of Rings7Chemaxon
Bioavailability1Chemaxon
Rule of FiveNoChemaxon
Ghose FilterNoChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleYesChemaxon